Gambaran Umum
Amicus Therapeutics, Inc. is a biotechnology company based in the United States, focused primarily on the discovery, development, and delivery of novel treatments for rare metabolic diseases. Founded in 2002 and headquartered in Cranbury, New Jersey, the company specializes in therapies that target unique diseases driven by genetic mutations. A significant project includes the development of migalastat, marketed under the name Galafold, which treats individuals with Fabry disease through an oral medication alternative to traditional enzyme replacement therapies. Additionally, Amicus is actively involved in advancing a pipeline that addresses other rare diseases, such as Pompe disease and Epidermolysis Bullosa, deploying innovative protein engineering and gene therapy technologies to cater to unmet medical needs in these patient populations.
Skor Kualitas, Nilai, dan Momentum
Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.
Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
- Nilai revenue untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah 571.16 MM.
- Nilai operating income untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah 25.05 MM.
- Nilai net income untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah -38.10 MM.
Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
2025-06-30 | 571.16 | 25.05 | -38.10 |
2025-03-31 | 543.14 | 47.79 | -29.37 |
2024-12-31 | 528.29 | 34.06 | -56.11 |
2024-09-30 | 493.67 | 14.40 | -104.69 |
2024-06-30 | 455.65 | -25.43 | -119.54 |
2024-03-31 | 423.49 | -57.78 | -147.07 |
2023-12-31 | 399.36 | -73.49 | -151.58 |
2023-09-30 | 372.37 | -110.55 | -173.61 |
2023-06-30 | 350.56 | -128.79 | -185.31 |
2023-03-31 | 336.79 | -171.90 | -204.24 |
2022-12-31 | 329.23 | -204.43 | -236.57 |
2022-09-30 | 323.29 | -234.09 | -263.98 |
2022-06-30 | 321.14 | -239.93 | -280.99 |
2022-03-31 | 317.83 | -217.25 | -270.06 |
2021-12-31 | 305.51 | -199.92 | -250.46 |
2021-09-30 | 293.93 | -193.88 | -238.58 |
2021-06-30 | 281.82 | -206.50 | -252.30 |
2021-03-31 | 266.76 | -219.31 | -253.57 |
2020-12-31 | 260.89 | -243.85 | -276.85 |
2020-09-30 | 245.61 | -267.86 | -295.18 |
Laporan Laba Rugi: EPS
- earnings per share basic untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.12.
- laba per saham yang terdilusi untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.12.
Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
2025-06-30 | -0.12 | -0.12 |
2025-03-31 | -0.10 | -0.10 |
2024-12-31 | -0.18 | |
2024-09-30 | -0.35 | -0.35 |
2024-06-30 | -0.40 | -0.40 |
2024-03-31 | -0.49 | -0.49 |
2023-12-31 | -0.51 | |
2023-09-30 | -0.59 | -0.59 |
2023-06-30 | -0.64 | -0.64 |
2023-03-31 | -0.70 | -0.70 |
2022-12-31 | -0.82 | |
2022-09-30 | -0.92 | -0.91 |
2022-06-30 | -0.99 | -0.99 |
2022-03-31 | -0.97 | -0.97 |
2021-12-31 | -0.92 | |
2021-09-30 | -0.90 | -0.90 |
2021-06-30 | -0.96 | -0.96 |
2021-03-31 | -0.97 | -0.97 |
2020-12-31 | -1.07 | -1.07 |
2020-09-30 | -1.15 | -1.15 |
Arus Kas: Operasi, Investasi, Pendanaan
- Nilai cash from operating activities untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah -45.66 MM.
- Nilai cash from investing activities untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah -24.76 MM.
- Nilai kas dari aktivitas pendanaan untuk Amicus Therapeutics, Inc. per 2025 Jun 30 adalah 7.19 MM.
Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
2025-06-30 | -45.66 | -24.76 | 7.19 |
2025-03-31 | 3.56 | -40.96 | 6.73 |
2024-12-31 | -33.89 | -0.56 | 5.12 |
2024-09-30 | -26.52 | -4.12 | 12.23 |
2024-06-30 | -41.89 | -2.63 | 31.66 |
2024-03-31 | -80.72 | 69.35 | 56.19 |
2023-12-31 | -69.09 | 98.06 | 61.68 |
2023-09-30 | -153.32 | 55.32 | 54.02 |
2023-06-30 | -126.60 | 94.07 | 15.85 |
2023-03-31 | -126.33 | 70.36 | -7.13 |
2022-12-31 | -166.57 | 92.32 | -7.46 |
2022-09-30 | -156.32 | 90.93 | -8.12 |
2022-06-30 | -168.39 | 50.99 | 193.55 |
2022-03-31 | -188.45 | 50.41 | 195.09 |
2021-12-31 | -202.49 | 78.76 | 212.07 |
2021-09-30 | -181.80 | 124.07 | 233.72 |
2021-06-30 | -200.11 | -64.56 | 271.32 |
2021-03-31 | -197.70 | -20.26 | 273.17 |
2020-12-31 | -233.29 | -13.58 | 262.86 |
2020-09-30 | -241.30 | 36.16 | 244.50 |
Metrik Penilaian: PE, PriceToBook, PriceToTBV
- p/e untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -60.07.
- p/libro untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah 9.12.
- p/tbv untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -85.53.
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
Period End (TTM) | p/e | P/Book | P/TBV |
2025-06-30 | -60.07 | 9.12 | -85.53 |
2025-03-31 | 13.35 | -123.63 | |
2024-12-31 | 15.72 | -76.00 | |
2024-09-30 | -26.57 | 23.97 | -37.76 |
2024-06-30 | -19.96 | 22.46 | -33.83 |
2024-03-31 | 21.87 | -60.28 | |
2023-12-31 | -23.99 | 31.25 | -48.49 |
2023-09-30 | -18.82 | 31.26 | -32.19 |
2023-06-30 | -17.51 | 34.87 | -37.57 |
2023-03-31 | -13.25 | 25.48 | |
2022-12-31 | 25.88 | -52.59 | |
2022-09-30 | 16.90 | -120.27 | |
2022-06-30 | 12.63 | 73.82 | |
2022-03-31 | -10.60 | 8.64 | 24.23 |
2021-12-31 | -13.49 | 8.55 | 18.00 |
2021-09-30 | -10.10 | 11.91 | 158.15 |
2021-06-30 | |||
2021-03-31 | -8.21 | 8.30 | 39.23 |
2020-12-31 | -7.41 | 7.17 | 23.16 |
2020-09-30 | -6.89 | 6.35 | 16.60 |
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
- EBIT/EV untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.00.
- EBIT (3 tahun) / EV untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.05.
Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
2025-06-30 | -0.00 | -0.05 |
2025-03-31 | -0.01 | -0.05 |
2024-12-31 | -0.02 | -0.05 |
2024-09-30 | -0.03 | -0.05 |
2024-06-30 | -0.05 | -0.07 |
2024-03-31 | -0.04 | -0.06 |
2023-12-31 | -0.04 | -0.05 |
2023-09-30 | -0.05 | -0.06 |
2023-06-30 | -0.06 | -0.06 |
2023-03-31 | -0.07 | -0.07 |
2022-12-31 | -0.07 | -0.07 |
2022-09-30 | -0.09 | -0.09 |
2022-06-30 | -0.08 | -0.08 |
2022-03-31 | -0.09 | -0.10 |
2021-12-31 | -0.07 | -0.09 |
2021-09-30 | -0.09 | -0.11 |
2021-06-30 | ||
2021-03-31 | -0.11 | -0.14 |
2020-12-31 | -0.12 | -0.14 |
2020-09-30 | -0.13 | -0.15 |
Efektivitas Manajemen
- roa untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.04.
- roe untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.22.
- roic untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.05.
- croic untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.04.
- ocroic untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah 0.01.
Period End (TTM) | ROA | ROE | ROIC (Tingkat Pengembalian Investasi Modal) | CROIC | OCROIC |
2025-06-30 | -0.04 | -0.22 | -0.05 | -0.04 | 0.01 |
2025-03-31 | -0.08 | -0.43 | -0.09 | -0.05 | -0.05 |
2024-12-31 | -0.13 | -0.65 | -0.17 | -0.05 | -0.04 |
2024-09-30 | -0.16 | -0.90 | -0.21 | -0.00 | -0.07 |
2024-06-30 | -0.21 | -1.43 | -0.26 | 0.08 | -0.14 |
2024-03-31 | -0.21 | -1.23 | -0.25 | 0.16 | -0.11 |
2023-12-31 | -0.23 | -1.31 | -0.30 | -0.03 | -0.26 |
2023-09-30 | -0.23 | -1.07 | -0.33 | -0.05 | -0.22 |
2023-06-30 | -0.26 | -1.18 | -0.33 | -0.05 | -0.22 |
2023-03-31 | -0.29 | -0.99 | -0.37 | -0.13 | -0.23 |
2022-12-31 | -0.28 | -0.70 | -0.45 | -0.18 | -0.27 |
2022-09-30 | -0.29 | -0.75 | -0.45 | -0.18 | -0.27 |
2022-06-30 | -0.34 | -1.26 | -0.45 | 0.10 | -0.27 |
2022-03-31 | -0.31 | -1.00 | -0.39 | 0.07 | -0.27 |
2021-12-31 | -0.27 | -0.83 | -0.34 | 0.11 | -0.22 |
2021-09-30 | -0.28 | -0.79 | -0.29 | 0.21 | -0.31 |
2021-06-30 | -0.36 | -0.70 | -0.38 | 0.02 | -0.31 |
2021-03-31 | -0.34 | -0.63 | -0.37 | 0.09 | -0.29 |
2020-12-31 | -0.33 | -0.58 | -0.38 | 0.03 | -0.32 |
2020-09-30 | -0.33 | -0.54 | -0.39 | 0.06 | -0.32 |
Gross Margins
- marjin kotor untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah 0.91.
- marjin bersih untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah -0.05.
- marjin operasi untuk Amicus Therapeutics, Inc. pada 2025 Jun 30 adalah 0.09.
- Margin Kotor
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Margin Keuntungan Bersih
- Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
- Margin Operasi
- Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) | Margin Kotor | Margin Keuntungan Bersih | Margin Operasi |
2025-06-30 | 0.91 | -0.05 | 0.09 |
2025-03-31 | 0.90 | -0.11 | 0.06 |
2024-12-31 | 0.90 | -0.21 | 0.03 |
2024-09-30 | 0.90 | -0.26 | -0.06 |
2024-06-30 | 0.90 | -0.35 | -0.14 |
2024-03-31 | 0.91 | -0.38 | -0.18 |
2023-12-31 | 0.90 | -0.47 | -0.30 |
2023-09-30 | 0.89 | -0.53 | -0.37 |
2023-06-30 | 0.89 | -0.53 | -0.37 |
2023-03-31 | 0.88 | -0.61 | -0.51 |
2022-12-31 | 0.89 | -0.82 | -0.72 |
2022-09-30 | 0.89 | -0.82 | -0.72 |
2022-06-30 | 0.89 | -0.87 | -0.68 |
2022-03-31 | 0.89 | -0.85 | -0.68 |
2021-12-31 | 0.88 | -0.82 | -0.65 |
2021-09-30 | 0.88 | -0.81 | -0.66 |
2021-06-30 | 0.88 | -0.90 | -0.73 |
2021-03-31 | 0.88 | -0.95 | -0.82 |
2020-12-31 | -1.06 | -0.93 | |
2020-09-30 | 0.88 | -1.20 | -1.09 |
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK) | 1178879 |
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations |